Home › Mantle Cell Lymphoma
Pag-aaral pangklinika para sa Mantle Cell Lymphoma na nagre-recruit sa U.S.
71 pag-aaral para sa Mantle Cell Lymphoma ang nagre-recruit ng mga kalahok sa mga site sa buong Estados Unidos.
Mga lungsod na may pinakamaraming pag-aaral
- Baldwin Park, CA16 pag-aaral
- Houston, TX15 pag-aaral
- Durham, NC13 pag-aaral
- Seattle, WA13 pag-aaral
- Columbus, OH12 pag-aaral
- New York City, NY12 pag-aaral
- Milwaukee, WI12 pag-aaral
- Boston, MA11 pag-aaral
- Chicago, IL10 pag-aaral
- Nashville, TN10 pag-aaral
- Portland, OR9 pag-aaral
- Rochester, MN9 pag-aaral
- Denver, CO8 pag-aaral
- Atlanta, GA8 pag-aaral
- St. Louis, MO8 pag-aaral
- Cleveland, OH7 pag-aaral
- Los Angeles, CA7 pag-aaral
- Mountain View, CA7 pag-aaral
- Dallas, TX6 pag-aaral
- Ann Arbor, MI6 pag-aaral
- Salt Lake City, UT6 pag-aaral
- Jacksonville, FL6 pag-aaral
- Miami, FL6 pag-aaral
- Philadelphia, PA5 pag-aaral
- Edison, NJ5 pag-aaral
- New Haven, CT5 pag-aaral
- Buffalo, NY5 pag-aaral
- Kansas City, MO5 pag-aaral
- San Diego, CA5 pag-aaral
- Baltimore, MD5 pag-aaral
- Tampa, FL5 pag-aaral
- Charlotte, NC5 pag-aaral
- Washington, DC5 pag-aaral
- Omaha, NE4 pag-aaral
- Queens, NY4 pag-aaral
- Providence, RI4 pag-aaral
- Richmond, VA4 pag-aaral
- Cedar Rapids, IA4 pag-aaral
- Minneapolis, MN4 pag-aaral
- San Francisco, CA4 pag-aaral
Ayos sa estado
- Alabama4 pag-aaral
- Arizona6 pag-aaral
- California31 pag-aaral
- Colorado10 pag-aaral
- Connecticut6 pag-aaral
- Delaware3 pag-aaral
- Florida16 pag-aaral
- Georgia9 pag-aaral
- Illinois10 pag-aaral
- Indiana4 pag-aaral
- Iowa5 pag-aaral
- Kansas7 pag-aaral
- Kentucky4 pag-aaral
- Louisiana3 pag-aaral
- Maryland9 pag-aaral
- Massachusetts13 pag-aaral
- Michigan8 pag-aaral
- Minnesota14 pag-aaral
- Missouri8 pag-aaral
- Nebraska4 pag-aaral
- New Jersey8 pag-aaral
- New York16 pag-aaral
- North Carolina17 pag-aaral
- Ohio17 pag-aaral
- Oregon10 pag-aaral
- Pennsylvania9 pag-aaral
- Rhode Island4 pag-aaral
- Tennessee11 pag-aaral
- Texas19 pag-aaral
- Utah6 pag-aaral
- Virginia7 pag-aaral
- Washington15 pag-aaral
- Wisconsin13 pag-aaral
Mga pag-aaral na kamakailan lamang in-update
Opisyal na teksto ng pag-aaral (English)
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 30, 2026 · NCT06542250The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 30, 2026 · NCT07285044Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 28, 2026 · NCT06252675A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 28, 2026 · NCT05006716A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 28, 2026 · NCT06697184A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 28, 2026 · NCT06742996Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment
Nagre-recruitObservasyonal na pag-aaral
Edad 18 pataas · Lahat ng kasarian · Na-update Set 23, 2026 · NCT06784167Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 23, 2026 · NCT06553872A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 22, 2026 · NCT07101328Zanubrutinib and Tafasitamab in Mantle Cell Lymphoma
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 21, 2026 · NCT06029309Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 9, 2026 · NCT07003295Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 9, 2026 · NCT07225439A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 8, 2026 · NCT06564038Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
Nagre-recruitPhase 3
Edad 60 pataas · Lahat ng kasarian · Na-update Set 2, 2026 · NCT05976763A Study of ARC-02 in B-cell NHL
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 26, 2026 · NCT07691606Nemtabrutinib With CAR T Therapy in Relapsed/Refractory Mantle Cell Lymphoma
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 17, 2026 · NCT07673367AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 12, 2026 · NCT06340737Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies
Nagre-recruitPhase 1
Edad 18 hanggang 85 · Lahat ng kasarian · Na-update Ago 10, 2026 · NCT05887167Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax
Nagre-recruitObservasyonal na pag-aaral
Edad 18 hanggang 110 · Lahat ng kasarian · Na-update Ago 7, 2026 · NCT05724121Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Nagre-recruitPhase 1/2
Edad 13 hanggang 90 · Lahat ng kasarian · Na-update Ago 6, 2026 · NCT06533579LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies
Nagre-recruitPhase 1
Edad 18 hanggang 81 · Lahat ng kasarian · Na-update Ago 6, 2026 · NCT05990465Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 5, 2026 · NCT06675123A Long-term Extension Study of PCI-32765 (Ibrutinib)
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 31, 2026 · NCT01804686A Study of APG-3288 in Relapsed/Refractory Blood Cancers
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 30, 2026 · NCT07424833This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 24, 2026 · NCT07121946Mula sa ClinicalTrials.gov, na-kuha noong Okt 1, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.